Five longevity drugs share one metabolic signature

Researchers compared the metabolic profiles of male mice treated with five validated longevity interventions: rapamycin, acarbose, 17α-estradiol, canagliflozin, and caloric restriction. Seven tissues per animal were analysed. The goal was to find shared metabolic changes across mechanistically distinct treatments.

The researchers found that metabolic profiles of treated mice diverged from controls early in life, well before survival differences emerged. A model trained on any four of the five interventions could correctly classify mice from the fifth, unseen intervention. This points to shared metabolic reprogramming independent of each treatment’s specific mechanism.

Ergothioneine as the common thread

Among all measured molecules, ergothioneine showed the most consistent elevation. This is a dietary antioxidant (a compound that limits cell damage caused by reactive molecules) that the body cannot synthesise on its own. Ergothioneine was elevated by all five interventions in plasma and brain, and by four of five in muscle.

Other shared changes were strongly tissue-specific. Lipid remodelling was observed in plasma, perigonadal fat, and kidney. The most informative molecules differed across tissues, making a single-biomarker blood test unrealistic for now.

Implications for longevity drug screening

The authors propose that metabolomic profiling could accelerate the screening of candidate anti-aging compounds. Rather than multi-year lifespan studies, early metabolic patterns might indicate whether a drug is promising.

A key limitation applies: the study compared only interventions known to extend lifespan. Without a comparison group of treatments that do not extend lifespan, it is unclear whether the identified patterns are truly specific to longevity. These findings are preliminary and have not yet undergone peer review. They are best read as hypothesis-generating rather than conclusive.

Read the original article